Brachytherapy with transperineal 125Iodine seeds for localized prostate cancer

被引:24
作者
Blank, LECM
Gonzalez, DG
de Reijke, TM
Dabhoiwala, NF
Koedooder, K
机构
[1] Acad Med Ctr, Dept Radiotherapy, NL-1100 DE Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Urol, NL-1105 AZ Amsterdam, Netherlands
关键词
prostate cancer; (125)Iodine seeds; brachytherapy; radiotherapy;
D O I
10.1016/S0167-8140(00)00231-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: To analyze the treatment results of transperineal (125)Iodine seeds in localized prostate cancer. Patients and methods: Between 1985 and 1996, 102 patients with T1-T2 NO prostate cancer were treated with transperineal (125)Iodine seed implants at the Academic Medical Centre in Amsterdam. Tumours were classified as T1c in four patients, T2a in 73 patients and T2b in 25 patients. The mean pre-treatment PSA was 17 ng/ml. The (125)Iodine seeds were implanted transperineally under transrectal ultrasound guidance. The mean prostate volume was 31 ml (range 15-48 ml). An average of 49 seeds (range 29-74) was implanted. The dose to the periphery of the prostate was 160 Gy. Until 1988, 27 patients had additional external pelvic irradiation to a dose of 40 Gy in 20 daily fractions of 2 Gy. Results: The 5- and 7-year actuarial survival rates were 77 and 63%, respectively (median 102 months). Ten patients (9.5%) died from prostate cancer. The 5- and 7-year clinical progression rates were 12 and 17%, respectively. Biochemical failure rates at 5 and 7 years were 39 and 44%, respectively. Age, alkaline phosphatase, creatinine, differentiation grade, additional treatment, staging procedure, number of seeds, prostate volume, treatment period and PSA were analyzed as prognostic factors. Only pre-treatment PSA was a prognosticator of clinical and biochemical outcome but not of survival. Biochemical control at 6 years varied from 30% for pre-treatment PSA values higher than 20 ng/ml to 95% for values less than or equal to 8 ng/ml. Forty-one out of 49 patients who were sexually active before brachytherapy maintained sexual function during the follow-up. Complete urinary incontinence occurred in one patient. No rectal complications were seen in patients receiving brachytherapy alone. Conclusions: Transperineal (125)Iodine seeds brachytherapy in localized prostate cancer achieves a good clinical control and overall survival with acceptable late toxicity. Biochemical failure was strongly correlated to the pre-treatment PSA value. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:307 / 313
页数:7
相关论文
共 37 条
  • [1] Arterbery VE, 1997, SEMIN SURG ONCOL, V13, P461, DOI 10.1002/(SICI)1098-2388(199711/12)13:6<461::AID-SSU11>3.0.CO
  • [2] 2-W
  • [3] PRELIMINARY-RESULTS WITH I-125 SEEDS FOR PERMANENT IMPLANTATION IN PATIENTS WITH LOCALIZED PROSTATIC-CANCER
    BATTERMANN, JJ
    BOON, TA
    DEVOOGT, HJ
    [J]. RADIOTHERAPY AND ONCOLOGY, 1987, 10 (02) : 91 - 95
  • [4] Biochemical disease-free survival following I-125 prostate implantation
    Beyer, DC
    Priestley, JB
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (03): : 559 - 563
  • [5] Centralized multiinstitutional postimplant analysis for interstitial prostate brachytherapy
    Bice, WS
    Prestidge, BR
    Grimm, PD
    Friedland, JL
    Feygelman, V
    Roach, M
    Prete, JL
    Dubois, DF
    Blasko, JC
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (04): : 921 - 927
  • [6] BLASKO JC, 1991, SCAND J UROL NEPHROL, P113
  • [7] Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
    Bolla, M
    Gonzalez, D
    Warde, P
    Dubois, JB
    Mirimanoff, RO
    Storme, G
    Bernier, J
    Kuten, A
    Sternberg, C
    Gil, T
    Collette, L
    Pierart, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (05) : 295 - 300
  • [8] Cox JD, 1997, INT J RADIAT ONCOL, V37, P1035
  • [9] Critz FA, 1998, CANCER J SCI AM, V4, P359
  • [10] Pd-103 brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma
    Dattoli, M
    Wallner, K
    Sorace, R
    Koval, J
    Cash, J
    Acosta, R
    Brown, C
    Etheridge, J
    Binder, M
    Brunelle, R
    Kirwan, N
    Sanchez, S
    Stein, D
    Wasserman, S
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 35 (05): : 875 - 879